<?xml version="1.0" encoding="UTF-8"?><AQE.QER VERSION="2"><QUESTION QID="E-007713-17" AIDREF="AE-007713-17" LEG.VAL="WQ"><HEAD.Q><TI1><P.WQ>Question for written answer<NO.WQ QID="Q-E-007713-17">E-007713-17</NO.WQ></P.WQ><P.WQ>to the<DEST.WQ ORG="COM"> Commission</DEST.WQ></P.WQ></TI1><TI2><P.WQ>Rule 130</P.WQ><P.WQ><AUTHOR.WQ PERSID="125012">Daniel Buda</AUTHOR.WQ><POL.GROUP GR="PPE">(PPE)</POL.GROUP></P.WQ></TI2><P.WQ><DATE.WQ DATE.DOC="20171213">(13 December 2017)</DATE.WQ></P.WQ></HEAD.Q><OBJ.Q OBJID="O-E-007713-17"><INT.OBJ.Q>Subject:</INT.OBJ.Q><TXT> Ineffective anti-cancer drugs have recently appeared on the market</TXT></OBJ.Q><CONTENTS CTNID="QC-E-007713-17"><P>A study by a team of public health researchers in London has shown that over half of new anti-cancer drugs in the&#xa0;EU have no beneficial effect on patients. Anti-cancer drugs produced between 2009-2013 have been shown to be ineffective on cancer patients. They have not contributed to lengthening survival rates or improving patients’ quality of life.</P><P>In the period in question, 48 anti-cancer drugs obtained authorisation for sale from the European Medicines Agency, with 68 specific indications. However, 57% of these treatments were approved without undergoing any tests to show their benefits in improving patients’ survival rates or quality of life.</P><P>These drugs have given false hope to cancer sufferers and mean extra expense for them, which in most cases is beyond their means.</P><P>What action can the Commission take to monitor these cases of ineffective anti-cancer drugs and what measures does it consider necessary to prevent such cases in future?</P></CONTENTS></QUESTION></AQE.QER>